The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
10.19746/j.cnki.issn1009-2137.2024.02.003
- VernacularTitle:维奈克拉联合阿扎胞苷治疗成人不适合强化疗急性髓系白血病的疗效及安全性分析
- Author:
Kai-Yue WANG
1
;
Bing-Ru FAN
;
Qian-Wen ZHANG
;
Meng-Ru HAN
;
Xiao-Yan GE
Author Information
1. 山西医科大学第二医院血液科,山西太原 030000
- Keywords:
venetoclax;
azacitidine;
unfit for intensive chemotherapy;
acute myeloid leukemia;
efficacy
- From:
Journal of Experimental Hematology
2024;32(2):342-346
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy and safety of venetoclax(VEN)combined with azacitidine(AZA)in the treatment of adult acute myeloid leukemia(AML)patients who are unfit for intensive chemotherapy.Methods:The clinical data of 21 adult patients with unfit AML who were treated with VEN combined with AZA in the Second Hospital of Shanxi Medical University from January 2021 to May 2022 were collected,and the efficacy and safety were analyzed retrospectively.Results:After one course of treatment with VEN and AZA,16 out of 21 unfit AML patients reached complete remission(CR)/CR with incomplete hematologic recovery(CRi),2 patients reached partial remission(PR),the overall response rate(ORR)was 85.7％.Among the 16 patients with CR/CRi,13 achieved minimal residual disease(MRD)negativity.Among the 11 patients with adverse prognosis,8 achieved CR/CRi.By the deadline of follow-up,the median overall suivival(OS)of the entire cohort was not reached,with 1-year OS rate of 61.7％.The main adverse events of VEN combined with AZA were myelosuppression,gastrointestinal reactions and infections.There were 13 cases of leukopenia,7 cases of neutropenia,7 cases of anemia,4 cases of thrombocytopenia,and these hematologic adverse events were all grade 3-4.There were 11 cases with gastrointestinal reactions and 7 cases with infections.The above adverse events were controllable and tolerable.No tumor lysis syndrome or infection related death occurred.Conclusion:VEN combined with AZA can quickly achieve deep remission in adult patients with unfit AML,and it shows a good safety profile.
